التفاصيل البيبلوغرافية
| العنوان: |
OnabotulinumtoxinA injection towards the SPG for treating symptoms of refractory chronic rhinosinusitis with nasal polyposis: a pilot study. |
| المؤلفون: |
Jamtøy, Kent Are, Tronvik, Erling, Bratbak, Daniel Fossum, Crespi, Joan, Stovner, Lars Jacob, Aschehoug, Irina, Thorstensen, Wenche Moe |
| المصدر: |
Acta Oto-Laryngologica; Oct 2021, Vol. 141 Issue 10, p934-940, 7p |
| مصطلحات موضوعية: |
NASAL polyps, BOTULINUM toxin, DRUG efficacy, PILOT projects, DIPLOPIA, DRUG delivery systems, CLINICAL trials, INJECTIONS, CHRONIC diseases, NERVE block, VISUAL analog scale, NOSE, RESPIRATORY obstructions, PRE-tests & post-tests, RHINORRHEA, SINUSITIS, DESCRIPTIVE statistics, LONGITUDINAL method |
| الملخص (بالإنجليزية): |
The main objective of this prospective, open, uncontrolled pilot study was to investigate the safety of administering onabotulinumtoxinA (BTA) towards the sphenopalatine ganglion (SPG) in 10 patients with refractory chronic rhinosinusitis with nasal polyposis (CRSwNP) using a novel injection tool, the MultiGuide®. A one-month baseline period was followed by bilateral injections of 25 U BTA in the SPG and a follow-up of 12 weeks. The primary outcome was adverse events (AE), and the main efficacy outcome was a 50% reduction in visual analogue scale (VAS) symptoms for nasal obstruction and rhinorrhea in months 2 and 3 post-treatment compared to baseline. We registered 13 AEs, none of which were serious, however, one patient experienced diplopia which moderately affected his daily activities. The symptoms slowly improved and resolved 4 weeks after injection. Five patients were treatment responders with at least 50% median reduction in the nasal obstruction, and four were treatment responders concerning rhinorrhea. Injection of BTA toward the SPG using the MultiGuide® in patients with CRSwNP appears to be safe but with a potential for moderately disabling side effects. The study indicates a beneficial effect on nasal obstruction. [ABSTRACT FROM AUTHOR] |
| Abstract (Chinese): |
背景和目标：这项前瞻性、开放、不受控制的试点研究的主要目的是为了研究使用新型注射工具 MultiGuideVR对10例难治性慢性鼻窦炎鼻息肉病（CRSwNP）患者的蝶腭神经节（SPG）注射肉毒杆菌毒素 A (BTA) 的安全性。 材料和方法： 1 个月的基线期后, 对SPG进行双侧注射 25 U BTA, 并有12 周的随访。主要结果是不良事件 (AE), 主要疗效结果是, 治疗后第 2 个月和第 3 个月, 与基线相比, 鼻塞和鼻漏的视觉模拟量表 (VAS) 症状减少 50%。 结果：我们记录到 13 个 AE, 没有一个是严重的。但是, 一名患者出现了复视, 对他的日常活动产生一定的影响。症状缓慢改善并在注射后4周内消退。 5 名患者是治疗反应者, 鼻塞的中位减少至少是50%。4 名患者是鼻漏的治疗反应者。 结论：使用 MultiGuideVR 向CRSwNP 患者的 SPG 注入 BTA似乎是安全的, 但有可能导致中度副作用。研究表明它对鼻塞有作用的。 [ABSTRACT FROM AUTHOR] |
|
Copyright of Acta Oto-Laryngologica is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
